USPTO grants notice of allowance for NAI’s sustained release beta-alanine

By Adi Menayang

- Last updated on GMT

USPTO grants notice of allowance to NAI’s SR CarnoSyn

Related tags United states patent and trademark office

The US Patent and Trademark Office has granted a Notice of Allowance for the branded, sustained-release beta-alanine ingredient SR CarnoSyn by Natural Alternatives International.

"This new patent is another integral component of NAI's SR CarnoSyn beta-alanine patent portfolio,”​ said Mark A. LeDoux, CEO and chairman of the board at California-based NAI. “These claims are an important part of our global strategy for providing performance increases well beyond those achievable through normal diets."

NAI's allowed application contains claims directed to human and animal dietary supplements containing sustained release beta-alanine in formulations that permit the release of beta-alanine over time, providing a steady, manageable rate of release following consumption, which helps the body's uptake of beta-alanine to form carnosine via a steady presence over time of beta-alanine in the blood system.  

This iteration of beta-alanine was first announced in the fall of 2015​. During its launch, the company marketed it as a beta-alanine alternative that delivers a higher amount of the bioactive more comfortably in a single dose than the original CarnoSyn, while eliminating the paresthesia (or prickling sensation) associated with taking the ingredient.

It achieved self-affirmed GRAS in April this year​.

Beta-alanine sales growth outpaces overall results

Last February, the NASDAQ-traded NAI reported that its income relating to beta-alanine sales​ rose 26.5% for its second quarter of fiscal 2017 ended Dec. 31, 2016.

In that time period, the company recorded $30.6 million in net sales—of that, $6.7 million came from beta-alanine royalties, licensing, and raw material sales.

​​With respect to our CarnoSyn beta-alanine business, we expect our current sales growth rate to continue for the balance of this fiscal year as we continue to expand our research, our patent estate and our client base,​​​​ the company stated earlier this year.

Related news

Show more

Related products

show more

Effera™ Human Equivalent Lactoferrin

Effera™ Human Equivalent Lactoferrin

Content provided by Helaina Inc | 17-May-2024 | Product Brochure

Helaina’s bioactive protein Effera™ is a novel branded ingredient and the first clinically studied Human Lactoferrin on the market. Human Lactoferrin is...

Related suppliers

Follow us


View more